睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由河南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方河南省肿瘤医院Henan Cancer Hospital郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07684950,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically and immunophenotypically confirmed mantle cell lymphoma.

    入选标准第 3 条

  3. Participants of reproductive potential must agree to use effective contraception during study treatment and for 3 months after the last dose of study treatment.

    入选标准第 13 条

    Concurrent participation in another clinical study. 3. Prior treatment with any BCL-2 inhibitor. 4. Active central nervous system involvement, including parenchymal or leptomeningeal disease.

    排除标准第 2 条

  4. Eastern Cooperative Oncology Group performance status of 0 to 2.

    入选标准第 6 条

  5. Total bilirubin ≤1.5 × upper limit of normal;

    入选标准第 9 条

    Creatinine clearance ≥30 mL/min;

    入选标准第 10 条

    Absolute neutrophil count ≥0.5 × 10\^9/L;

    入选标准第 11 条

    Platelet count ≥30 × 10\^9/L. Supportive treatment is permitted.

    入选标准第 12 条

  6. Positive human immunodeficiency virus test. 9. Active hepatitis B or hepatitis C infection, except:

    排除标准第 6 条

  7. Pregnant or breastfeeding women. 11. Unable to complete protocol-required study visits or procedures, including follow-up visits, or unable to comply with study requirements.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07684950,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants must meet all of the following criteria:
  2. Age 18 years or older.
  3. Histologically and immunophenotypically confirmed mantle cell lymphoma.
  4. At least one measurable lesion.
  5. Received at least one prior systemic treatment regimen that included a BTK-targeted therapy, including a covalent BTK inhibitor, non-covalent BTK inhibitor, or BTK degrader, and had stable disease, disease progression, or intolerance during or after the most recent BTK-targeted therapy.
  6. Eastern Cooperative Oncology Group performance status of 0 to 2.
  7. Adequate hepatic, renal, and bone marrow function, defined as all of the following:
  8. Aspartate aminotransferase and alanine aminotransferase ≤3 × upper limit of normal;
  9. Total bilirubin ≤1.5 × upper limit of normal;
  10. Creatinine clearance ≥30 mL/min;
  11. Absolute neutrophil count ≥0.5 × 10\^9/L;
  12. Platelet count ≥30 × 10\^9/L. Supportive treatment is permitted.
  13. Participants of reproductive potential must agree to use effective contraception during study treatment and for 3 months after the last dose of study treatment.
  14. Willing and able to comply with study procedures and follow-up assessments.
  15. Able to understand and voluntarily sign the informed consent form before screening.

排除标准:Exclusion Criteria:

  1. 1. Known hypersensitivity to pirtobrutinib, lisaftoclax, or any component or excipient of either study drug.
  2. Concurrent participation in another clinical study. 3. Prior treatment with any BCL-2 inhibitor. 4. Active central nervous system involvement, including parenchymal or leptomeningeal disease.
  3. Clinically significant uncontrolled cardiac or cardiovascular disease, or a history of myocardial infarction within 6 months before the planned initiation of pirtobrutinib.
  4. Uncontrolled active severe systemic bacterial, viral, fungal, or parasitic infection.
  5. Current treatment with strong CYP3A4 inhibitors or inducers and/or strong P-glycoprotein inhibitors.
  6. Positive human immunodeficiency virus test. 9. Active hepatitis B or hepatitis C infection, except:
  7. Participants with detectable hepatitis B virus DNA whose disease is controlled may be enrolled at the investigator's discretion, provided that concurrent antiviral therapy is administered;
  8. Participants with a history of hepatitis C virus infection who have completed antiviral treatment and have a viral load below the lower limit of quantification may be enrolled.
  9. Pregnant or breastfeeding women. 11. Unable to complete protocol-required study visits or procedures, including follow-up visits, or unable to comply with study requirements.
  10. Any other clinically significant current or prior medical condition that, in the investigator's judgment, may pose a risk to participant safety or interfere with study assessments, procedures, or completion.

引自 ClinicalTrials.gov, NCT07684950, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07684950,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07684950